Literature DB >> 24236889

Bifunctional oligodeoxynucleotide/antagomiR constructs: evaluation of a new tool for microRNA silencing.

Saskia Ziegler1, Mariel Esther Eberle, Sabine J Wölfle, Klaus Heeg, Isabelle Bekeredjian-Ding.   

Abstract

MicroRNAs (miRNAs) are fine-tuners in cellular processes, including those of the immune response. To study their functions and effects in immune cells, it is necessary to achieve specific silencing of individual miRNAs. To date, introduction of antisense microRNAs (antagomiRs) into primary cells is based on electroporation, lipofection, and viral vectors. However, these techniques often compromise viability, proliferative capacity, and differentiation. Furthermore, efficiency varies depending on the cell type and some are not suitable for in vivo approaches. To overcome these limitations we exploited the property of phosphorothioate (PTO)-modified DNA oligodeoxynucleotides (ODN) to enter cells with high efficacy: we developed and evaluated ODN/antagomiR constructs that consist of a PTO-ODN carrier covalently linked to a fully methylated antagomiR RNA sequence. Using these constructs, we achieved transfection efficiency of approximately 99% in leukocytes-in particular, in B lymphocytes that are hard to transfect with other methods. Our data demonstrate that miRNA silencing by the antagomiR portion of the constructs was specific and efficient, which could be further confirmed by an increase in target protein under silencing conditions. The constructs were successfully tested in human B cells, plasmacytoid dendritic cells, monocytes, and monocyte-derived dendritic cells, thus demonstrating their versatility. Moreover, introduction of stimulatory CpG sequences into the ODN portion conveys immune stimulatory quality when intended. Thus, bifunctional ODN/antagomiR constructs represent a highly efficient, versatile, and easy-to-handle tool to manipulate cellular miRNA expression levels and to allow the subsequent investigation of specific miRNA functions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24236889     DOI: 10.1089/nat.2013.0447

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  6 in total

1.  MicroRNAs and cancer: Key paradigms in molecular therapy.

Authors:  Weige Tan; Bodu Liu; Shaohua Qu; Gehao Liang; Wei Luo; Chang Gong
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

2.  B Cells Produce Type 1 IFNs in Response to the TLR9 Agonist CpG-A Conjugated to Cationic Lipids.

Authors:  Munir Akkaya; Billur Akkaya; Pietro Miozzo; Mukul Rawat; Mirna Pena; Patrick W Sheehan; Ann S Kim; Olena Kamenyeva; Juraj Kabat; Silvia Bolland; Akanksha Chaturvedi; Susan K Pierce
Journal:  J Immunol       Date:  2017-06-26       Impact factor: 5.422

Review 3.  Synthetic RNAs for Gene Regulation: Design Principles and Computational Tools.

Authors:  Alessandro Laganà; Dennis Shasha; Carlo Maria Croce
Journal:  Front Bioeng Biotechnol       Date:  2014-12-11

4.  Direct uptake of Antagomirs and efficient knockdown of miRNA in primary B and T lymphocytes.

Authors:  Claudia Haftmann; René Riedel; Martina Porstner; Jürgen Wittmann; Hyun-Dong Chang; Andreas Radbruch; Mir-Farzin Mashreghi
Journal:  J Immunol Methods       Date:  2015-07-15       Impact factor: 2.303

Review 5.  The Potentials and Pitfalls of Microarrays in Neglected Tropical Diseases: A Focus on Human Filarial Infections.

Authors:  Alexander Kwarteng; Samuel Terkper Ahuno
Journal:  Microarrays (Basel)       Date:  2016-08-02

6.  Hsa-miR-99b/let-7e/miR-125a Cluster Regulates Pathogen Recognition Receptor-Stimulated Suppressive Antigen-Presenting Cells.

Authors:  Dagmar Hildebrand; Mariel-Esther Eberle; Sabine Marie Wölfle; Franziska Egler; Delal Sahin; Aline Sähr; Konrad A Bode; Klaus Heeg
Journal:  Front Immunol       Date:  2018-06-18       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.